Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 10, Number 10—October 2004
Research

Fluoroquinolone Resistance in Penicillin-resistant Streptococcus pneumoniae Clones, Spain

Adela G. de la Campa*Comments to Author , Luz Balsalobre*, Carmen Ardanuy†, Asunción Fenoll*, Emilio Pérez-Trallero‡, Josefina Liñares†, and the Spanish Pneumococcal Infection Study Network G03/103
Author affiliations: *Instituto de Salud Carlos III, Majadahonda, Madrid, Spain; †Hospital de Bellvitge, L’Hospitalet de Llobregat, Barcelona, Spain; ‡Hospital Donostia, San Sebastian, Guipúzcoa, Spain

Main Article

Table 3

Summary of phenotypic characteristics and changes in the QRDR among the most prevalent pulsed-field gel electrophoresis patterns of ciprofloxacin-resistant strainsa

PFGE Strain Serotype Resistance pattern aa and nt changes in QRDR
ParC ParE GyrA
Referent R6 NT S None None None
Spain23F-1 CipR-8 23F PEClTCSxTCp G128 (GGT), K137N, S79F I460V, I476 (ATT) Y75 (TAT)
CipR-5 19Ab PTCSxTCp G128 (GGT), K137N, S79F I460V, I476 (ATT) Y75 (TAT)
CipR-9 23F PEClTCSxTCp G128 (GGT), K137N, S79Y I460V, I476 (ATT) Y75 (TAT)
CipR-12 23F PTCCp G128 (GGT), K137N, D83G I460V, I476 (ATT) Y75 (TAT)
CipR-30, -31, -32, -33 23F PEClTCSxTCp G128 (GGT), K137N, S79F I460V, I476 (ATT) Y75 (TAT), S81F
CipR-48, -49 23F PEClTCSxTCp G128 (GGT), K137N, S79F I460V, I476 (ATT) Y75 (TAT), E85K

CipR-73
19Ab
EClTSxTCp
S79F
None
Y75 (TAT), S81F
Spain14-5 CipR-24 14 PEClTCSxTCp S79F None Y75 (TAT), S81F
CipR-41 14 PEClTCSxTCp S79F None Y75 (TAT), S81Y
CipR-55 14 PEClTCSxTCp S79Y None Y75 (TAT), S81F
CipR-66, -67 14 PEClTCSxTCp S79F D435N Y75 (TAT), E85K

CipR-38, -39, -40
14
PEClTCSxTCp
S79F
None
Y75 (TAT), V88I, S81Y
Spain9V-3 CipR-10 9V PSxTCp K137N, S79Y I460V Y75 (TAT)
CipR-14 14b PESxTCp K137N, S79A I460V Y75 (TAT), S81F
CipR-51 14b PSxTCp K137N, S79Y I460V Y75 (TAT), S81F
CipR-20 9V PSxTCp K137N, S79F I460V Y75 (TAT), S81F
CipR-28 19Fb PSxTCp K137N, S79F I460V Y75 (TAT), S81F

CipR-58
14b
PSxTCp
K137N, D83N
I460V
Y75 (TAT), S81F
Spain6B-2 CipR-3 6B PEClTSxTCp S79F None Y75 (TAT)
CipR-17, -18, -19 6B PEClTCSxTCp S79F None Y75 (TAT), S81F

CipR-72
6B
PEClTSxTCp
S79F
None
Y75 (TAT), S81F
Sweden15A-25 CipR-4 15A PEClTCp G77 (GGA), S79F I460V Y75 (TAT)
CipR-64 15A PEClTCp G77 (GGA) I460V, D435N Y75 (TAT), S81Y
CipR-60 15A PEClTCp G77 (GGA), D83Y I460V Y75 (TAT), E85K

CipR-45, -50
15A
PEClTCp
G77 (GGA), S79F
I460V
Y75 (TAT), E85K
C CipR-59 19F PTCSxTCp D83N None Y75 (TAT), S81F
CipR-43, -44 19F PTCSxTCp S79F None Y75 (TAT), S81Y

CipR-65
19F
PEClTCSxTCp
S79Y, D83N
None
Y75 (TAT), E85K
D CipR-57 19F PEClTCp G77 (GGA), S79Y I460V, P454S Y75 (TAT), S81Y
CipR-29 19F PEClTCCp G77 (GGA), S79F I460V Y75 (TAT), S81F

CipR-46, -47
19F
PEClTCp
G77 (GGA), S79F
I460V
Y75 (TAT), E85K
A CipR-1 3 Cp R95C, S79F I460V Y75 (TAT), H104 (CAC)
CipR-2 3 Cp R95C, S79F None Y75 (TAT), H104 (CAC)

CipR-15
3
TCCp
R95C, S79F
None
Y75 (TAT), H104 (CAC), S81F
B CipR-61 3 Cp None I460V, D435N Y75 (TAT), S81F
CipR-52 3 ECp S79Y I460V Y75 (TAT), S81F

aQRDR, quinolone-resistance determining regions; PFGE, pulse-field gel electrophoresis SmaI patterns; aa, amino acid; nt, nucleotide; S, susceptible to all antibiotics tested; P, resistant to penicillin (MIC 0.12–4 μg/mL); T, resistant to tetracycline (MIC >4 μg/mL); C, resistant to chloramphenicol (MIC >8 μg/mL); E, resistant to erythromycin (MIC >0.5 μg/mL); Cl, resistant to clindamycin (MIC >0.5 μg/mL); SxT, resistant to trimethropin-sulfamethoxazole (MIC >4/76 μg/mL); Cp, resistant to ciprofloxacin (MIC >4 μg/mL). Residue changes involved in fluoroquinolone resistance are showed in boldface, and double underlining indicates that the residue is located in a gene with a mosaic structure. A, PFGE type related to serotype 3 with MLST 260; B, PFGE type related to serotype 3 with MLST 180; NT, non typeable.
bCapsular switching.

Main Article

1Spanish Pneumococcal Infection Study Network—general coordination: Román Pallarés; participants and centers: Ernesto García (Centro de Investigaciones Biológicas, Madrid); Julio Casal, Asuncion Fenoll, Adela G. de la Campa (Centro Nacional de Microbiología, Instituto de Salud Carlos III, Madrid); Emilio Bouza, (Hospital Gregorio Marañon, Madrid); Fernando Baquero (Hospital Ramón y Cajal, Madrid); Francisco Soriano, José Prieto (Fundación Jiménez Díaz y Hospital Clínico, Madrid); Román Pallarés, Josefina Liñares (Hospital Universitari de Bellvitge, Barcelona); Javier Garau, Javier Martínez Lacasa (Hospital Mutua de Terrassa, Barcelona); Cristina Latorre (Hospital Sant Joan de Deu, Barcelona); Emilio Pérez-Trallero, Alberto González (Hospital Donostia, San Sebastian); Juan García de Lomas (Hospital Clínico, Valencia); and Ana Fleites (Hospital Central de Asturias).

Page created: April 11, 2011
Page updated: April 11, 2011
Page reviewed: April 11, 2011
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external